Brief: Sernova Announces Initial Islet Transplantation In First Two Patients Enrolled For Type 1 Diabetes Treatment Trial
08/03/2023 12:33
March 8 (Reuters) - Sernova Corp SVA.TO :
* SERNOVA ANNOUNCES INITIAL ISLET TRANSPLANTATION IN FIRST
TWO
PATIENTS ENROLLED IN SECOND COHORT OF ITS U.S. PHASE 1/2
CLINICAL TRIAL FOR TREATMENT OF TYPE 1 DIABETES
* SERNOVA CORP - COMPANY ANTICIPATES FIRST INTERIM DATA FROM
SECOND COHORT IN Q4 2023
* SERNOVA CORP - THIRD PATIENT NOW IMPLANTED WITH HIGHER
CAPACITY,
10-CHAMBER CELL POUCH
Source text for Eikon: ID:nGNX31sw70
Further company coverage: SVA.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sernova Biotherapeutics
See all newsBrief: Seraxis And Sernova Announce Appointment Of Former FDA Medical Officer Dr. Patricia Beaston As Chief Medical Officer Of Seraxis And Post Merger Betanova Biotherapeutics
Brief: Sernova Appoints Jonathan Rigby As Interim Chair
Brief: Sernova Biotherapeutics Provides Positive Interim Data From Ongoing Phase 1/2 Clinical Trial Of Cell Pouch Bio-Hybrid Organ In Patients Living With Type 1 Diabetes
Brief: Sernova Biotherapeutics Secures $4 Million Loan To Further Advance Its Clinical Development Plans
Brief: Sernova Biotherapeutics Inc Study Is On Track To Meet Key Clinical Trial Endpoints